BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Mobius Theraputics™ Awarded Grant


9/24/2009 10:48:58 AM

ST. LOUIS, MO--(Marketwire - September 24, 2009) -

Mobius Therapeutics, LLC ™ has been awarded a research grant from the National Institute on Deafness and other Communication Disorders (NIDCD) to study its investigational procedure, selective Photodynamic Myringotomy (PDM).

PDM is a procedure where the tympanic membrane (ear drum) is treated with a specially stained anti-scarring agent. The stained tissue is then exposed to a specially tuned laser, designed to be absorbed only at the site of the stain. The procedure treats ear infections by opening the membrane to ventilate and drain the ear. The anti-scarring agent slows the healing process which allows the ear to stay ventilated, while eliminating the need for pressure equalization tubes and the associated surgery.

"The potential of PDM is enormous," said Ed Timm, President of Mobius Therapeutics. "Otitis media is the single most common reason for a child to visit the doctor. In the USA alone, bilateral myringotomy with tubes accounts for an estimated 2,000,000 surgeries each year on children under the age of 16. The ability to replace an anesthetized hospital surgical procedure with a single, painless office procedure would be welcomed by both children and parents."

"This grant will allow Mobius to achieve measurable milestones," Timm continued. "The rapid issuance of broad patent protection compelled us to accelerate the development of PDM. We are grateful to NIDCD and corporate supporters that have made this development possible."

About Mobius Therapeutics™:

Mobius Therapeutics, LLC™ is an early stage venture focused on glaucoma and otologic surgery solutions. Its first product, Trabomycin™, is a system for delivering antifibrotic agents in glaucoma surgery. It is awaiting regulatory approval, with additional product applications in earlier stages of development. Mobius relocated from Atlanta to St. Louis in July 2007 and is a portfolio company of The Incubation Factory of St. Louis.


For more information, contact:

Ed Timm
Mobius Therapeutics, LLC™
1141 South 7th Street
St. Louis, MO 63104

PHONE: +1 314-571-6205
FAX: +1 314-450-5933
E-MAIL: Email Contact



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES